The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-08. Anything still debated is marked as such rather than presented as settled.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
=== 1982–1994 === The company established its presence in the US in 1982 via a joint venture with Squibb Corporation and Canada in 1984. In 1985, the company introduced the first insulin pen device called Novopen. In 1989, Novo Industri (Novo Terapeutisk Laboratorium) and Nordisk Gentofte (Nordisk Insulinlaboratorium) merged to become Novo Nordisk, the world's largest producer of insulin with headquarters in Bagsværd, Greater Copenhagen. In 1991, Novo Nordisk Engineering (now NNE) demerged after working as in-house consultants at Novo for years, to provide standard engineering services (end-to-end engineering) to pharma manufacturing companies. In 1994, Novo's existing information technology units was spun out as NNIT. The company was converted into a wholly owned aktieselskab in 2004. In March 2015, NNIT was floated on the Nasdaq Nordic.
=== Nanoparticle-Protein Interactions === ITC is increasingly utilized to study protein-nanoparticle interactions by providing key insights into binding affinity (in the form of association constant), interaction mechanisms (quantified through binding enthalpy, binding entropy, and Gibbs free energy), and binding stoichiometry. These thermodynamic parameters from ITC can help assess structural modifications in proteins upon adsorption onto nanoparticle surfaces.
=== Operation Edzell === An undercover policewoman from the Metropolitan Police Special Operations Group (SO10) contacted Stagg, posing as a friend of a woman with whom he used to be in contact via a lonely hearts' column. Over five months, she attempted to obtain information from him by feigning a romantic interest, meeting him, speaking to him on the telephone and exchanging letters containing sexual fantasies. During a meeting in Hyde Park, they spoke about the Nickell homicide; he later said that he had only played along with the topic because he wanted to pursue the romance. Profiler Paul Britton later said that he disagreed with use of the fantasy-filled letters and knew nothing of them until after they had been sent. The undercover officer won Stagg's confidence and drew out fantasies from him that psychologist Paul Britton interpreted as "violent", but he did not admit to the killing. Police released a taped conversation between the police officer and him, in which she claimed to enjoy hurting people, to which he mumbled, "Please explain, as I live a quiet life. If I have disappointed you, please don't dump me. Nothing like this has happened to me before". When she went on to say, "If only you had done the Wimbledon Common murder, if only you had killed her, it would be all right", he replied, "I'm terribly sorry, but I haven't". Stagg was nevertheless arrested and charged on the basis of claims that he had described aspects of the murder scene that only the killer would have known.
== Safety == It is considered "essentially nontoxic". Benzophenone is however banned as a food additive by the US Food and Drug Administration, despite the FDA's continuing stance that this chemical does not pose a risk to public health under the conditions of its intended use. The European Union permits it as a flavouring substance, having established a Total Dietary Intake of 0.3mg/kg of body weight per day. Benzophenone derivatives are known to be pharmacologically active. From a molecular chemistry point of view interaction of benzophenone with B-DNA has been demonstrated experimentally. The interaction with DNA and the successive photo-induced energy transfer is at the base of the benzophenone activity as a DNA photosensitizer and may explain part of its therapeutic potentialities. In 2014, benzophenones were named Contact Allergen of the Year by the American Contact Dermatitis Society. Benzophenone is an endocrine disruptor capable of binding to the pregnane X receptor.
Sources: en.wikipedia.org
Glaucoma is a progressive optic neuropathy where retinal ganglion cells and their axons die causing a corresponding visual field defect. An important risk factor is increased intraocular pressure (pressure within the eye) either through increased production or decreased outflow of aqueous humour. Increased resistance to outflow of aqueous humour may occur due to an abnormal trabecular meshwork or due to obliteration of the meshwork resulting from injury or disease of the iris. However, increased interocular pressure is neither sufficient nor necessary for development of primary open angle glaucoma, although it is a major risk factor. Uncontrolled glaucoma typically leads to visual field loss and ultimately blindness. Uveoscleral outflow of aqueous humour can be increased with prostaglandin agonists, while trabecular outflow is increased by M3 agonists. Fluid production can be decreased by beta blockers, alpha2-agonists, and carbonic anhydrase inhibitors.
=== Chemical precursor === A number of useful compounds are made from acrolein, exploiting its bifunctionality. The amino acid methionine is produced by addition of methanethiol followed by the Strecker synthesis. Acrolein condenses with acetaldehyde and amines to give methylpyridines. It is also an intermediate in the Skraup synthesis of quinolines. Acrolein will polymerize in the presence of oxygen and in water at concentrations above 22%. The color and texture of the polymer depends on the conditions. The polymer is a clear, yellow solid. In water, it will form a hard, porous plastic. Acrolein has been used as a fixative in preparation of biological specimens for electron microscopy.
electroporation Also electropermeabilization. A molecular biology technique in which a strong electric field is applied to living cells in order to temporarily increase the permeability of their cell membranes, allowing exogenous nucleic acids, proteins, or chemical compounds to easily pass through the membrane and thereby enter the cells. It is a common method of achieving transformation and transfection.
Morphine is a benzylisoquinoline alkaloid with two additional ring closures. As Jack DeRuiter of the Department of Drug Discovery and Development (formerly, Pharmacal Sciences), Harrison School of Pharmacy, Auburn University stated in his Fall 2000 course notes for that earlier department's "Principles of Drug Action 2" course, "Examination of the morphine molecule reveals the following structural features important to its pharmacological profile... A rigid pentacyclic structure consisting of a benzene ring (A), two partially unsaturated cyclohexane rings (B and C), a piperidine ring (D) and a tetrahydrofuran ring (E). Rings A, B, and C are the phenanthrene ring system. This ring system has little conformational flexibility... Two hydroxyl functional groups: a C3-phenolic [hydroxyl group] (pKa 9.9) and a C6-allylic [hydroxyl group], An ether linkage between E4 and E5, Unsaturation between C7 and C8, A basic, [tertiary]-amine function at position 17, [and] [Five] centers of chirality (C5, C6, C9, C13, and C14) with morphine exhibiting a high degree of stereoselectivity of analgesic action." Morphine and most of its derivatives do not exhibit optical isomerism, although some more distant relatives like the morphinan series (levorphanol, dextrorphan, and the racemic parent chemical racemorphan) do, and as noted above stereoselectivity in vivo is an important issue.
== History == Oat products have been used for centuries for medicinal and cosmetic purposes; however, the specific role of β-glucan was not explored until the 20th century. β-glucans were first discovered in lichens, and shortly thereafter in barley. After joining Agriculture and Agri-Food Canada in 1969, Peter J Wood played an instrumental role in isolating and characterizing the structure and bioactive properties of oat β-glucan. A public interest in oat β-glucan arose after its cholesterol lowering effect was reported in 1984. In 1997, after reviewing 33 clinical studies performed over the previous decades, the FDA approved the claim that intake of at least 3 g of β-glucan from oats per day "as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease." This marked the first time a public health agency claimed dietary intervention can actually help prevent disease. This health claim mobilized a dietary movement as physicians and dietitians for the first time could recommend intake of a specific food to directly combat disease. Since then, oat consumption has continued to gain traction in disease prevention with noted effects on ischemic heart disease and stroke prevention, but also in other areas like BMI reduction, blood pressure lowering and highly corroborated evidence for reduced blood serum cholesterol.
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.